FDA
-
-
-
-
-
-
-
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
-
-
-
-
-
-
-
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
-
-
-
-
-
-
-
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Stoke Therapeutics and Biogen present 3-year zorevunersen data for Dravet
-
-
-
-
-
-
-
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
330,678 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

